One year later, another Italian group published their findings, also with a 12-week open-label study
, in which they evaluated the efficacy of quetiapine in 23 male and female outpatients with borderline personality disorder (Prog.
Kerdel and his associates have conducted an open-label study
of etanercept re-treatment in 20 patients with moderate to severe psoriasis (defined as a PGA score of 3 or greater) who had had prior therapy with etanercept for a minimum of 6 months but had discontinued it because of loss of efficacy.
Another group of investigators conducted a 6-month open-label study
of 541 patients diagnosed with a bipolar disorder (66.2%) or schizoaffective disorder, bipolar type (33.8%) (J.
The open-label study
, sponsored by Johnson and Johnson Pharmaceutical Research and Development, included 204 children with confirmed acute otitis media who received at least one 10-mg/kg dose of the study medication (Pediatr.
Naratriptan appeared to be effective for treating refractory chronic migraine in a retrospective, open-label study
of 27 patients, Dr.
Zai Lab (ZLAB) announced publication of the open-label study
evaluating the pharmacokinetic profile of niraparib in Chinese ovarian cancer patients.
Medivir AB (STO:MVIRB) announced on Monday that a phase IIb open-label study
of the combination of simeprevir, odalasvir and AL-335, also known as JNJ-4178, has been initiated by Janssen Research & Development LLC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), in treatment-naive and treatment-experienced subjects with chronic hepatitis C virus infection without cirrhosis.
The Phase 1/2 trial is a prospective, open-label study
designed to determine the safety and tolerability of the hESC-derived RPE cells following sub-retinal transplantation into patients with dry AMD.
The label includes a summary of an open-label study
of 275 adults with leukemia, lymphoma, and solid tumor malignancies who were at risk for hyperuricemia and tumor lysis syndrome.
In a third phase of the study, of 136 patients who had improved with TMS therapy in the initial study and in the open-label study
, who were able to resume medication, an interim analysis at 4 weeks indicated that the relapse rate was low.